Which response by the PMHNP describes nthe factors that contribute to reduced risk of extrapyramidal symptoms (EPS) for patients who take antipsychotics?

1. The student inquires about antipsychotic medications. Which response by the PMHNP describes nthe factors that contribute to reduced risk of extrapyramidal symptoms (EPS) for patients who take antipsychotics?

A.

Those that are potent D2 antagonists

B.

Those that are potent D2 antagonists with 5HT2A antagonism properties

C.

D2 receptors that are blocked in the nigrostriatal pathway

D.

Potent D2 antagonists that block the muscarinic anti-M1 cholinergic receptors

Place Your Order Here!